Letter re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

被引：0
|
作者：
Ding, Qian [1 ]
Guan, Ming-Cheng [1 ]
Zhu, Hong [1 ,2 ]
机构：
[1] Soochow Univ, Dept Med Oncol, Affiliated Hosp 1, Suzhou 215006, Peoples R China
[2] Soochow Univ, Dept Med Oncol, Affiliated Hosp 1, 899,Pinghai Rd, Suzhou 215006, Jiangsu, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2023年 / 192卷
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1016/j.ejca.2023.113263
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma
    Kim, Hyung-Don
    Park, Young-Gyu
    Kim, Sejin
    Kim, Kyu-Pyo
    Park, Sook-Ryun
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Yoo, Changhoon
    HEPATOLOGY INTERNATIONAL, 2024, 18 (03) : 973 - 983
  • [22] Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis
    Peng, Tzu-Rong
    Weng, Yi-Fang
    Wu, Ta-Wei
    Wu, Chao-Chuan
    Chou, Yi-Chun
    Hsu, Ching-Sheng
    CANCERS, 2024, 16 (16)
  • [23] Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab (KCSG HB23-04)
    Yoo, C.
    Kim, H-D.
    Chon, H. J.
    Sym, S. J.
    Kim, M.
    Kang, J. H.
    Ryoo, B-Y.
    Lee, C-K.
    Hong, J.
    Ryu, H.
    Bae, W. K.
    Kim, H.
    Kim, H.
    Kim, J. W.
    Kim, T-Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1450 - S1450
  • [24] Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
    Niizeki, Takashi
    Tokunaga, Takayuki
    Takami, Yuko
    Wada, Yoshiyuki
    Harada, Masaru
    Shibata, Michihiko
    Nakao, Kazuhiko
    Sasaki, Ryu
    Hirai, Fumihito
    Shakado, Satoshi
    Yoshizumi, Tomoharu
    Itoh, Shinji
    Yatsuhashi, Hiroshi
    Bekki, Shigemune
    Ido, Akio
    Mawatari, Seiichi
    Honda, Koichi
    Sugimoto, Rie
    Senju, Takeshi
    Takahashi, Hirokazu
    Kuwashiro, Takuya
    Maeshiro, Tatsuji
    Nakamuta, Makoto
    Aratake, Yoshifusa
    Yamashita, Tsutomu
    Otsuka, Yuichiro
    Matsumoto, Shuichi
    Sohda, Tetsuro
    Shimose, Shigeo
    Murotani, Kenta
    Tanaka, Yasuhito
    TARGETED ONCOLOGY, 2022, 17 (06) : 643 - 653
  • [25] Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
    Takashi Niizeki
    Takayuki Tokunaga
    Yuko Takami
    Yoshiyuki Wada
    Masaru Harada
    Michihiko Shibata
    Kazuhiko Nakao
    Ryu Sasaki
    Fumihito Hirai
    Satoshi Shakado
    Tomoharu Yoshizumi
    Shinji Itoh
    Hiroshi Yatsuhashi
    Shigemune Bekki
    Akio Ido
    Seiichi Mawatari
    Koichi Honda
    Rie Sugimoto
    Takeshi Senju
    Hirokazu Takahashi
    Takuya Kuwashiro
    Tatsuji Maeshiro
    Makoto Nakamuta
    Yoshifusa Aratake
    Tsutomu Yamashita
    Yuichiro Otsuka
    Shuichi Matsumoto
    Tetsuro Sohda
    Shigeo Shimose
    Kenta Murotani
    Yasuhito Tanaka
    Targeted Oncology, 2022, 17 : 643 - 653
  • [26] Outcomes of patients with Child-Pugh B and unresectable hepatocellular carcinoma undergoing first-line systemic treatment with sorafenib, lenvatinib, or atezolizumab plus bevacizumab
    Kikugawa, Chihiro
    Uchikawa, Shinsuke
    Kawaoka, Tomokazu
    Kinami, Takahiro
    Yano, Shigeki
    Amioka, Kei
    Naruto, Kensuke
    Ando, Yuwa
    Yamaoka, Kenji
    Tsuge, Masataka
    Kosaka, Yumi
    Ohya, Kazuki
    Mori, Nami
    Takaki, Shintaro
    Tsuji, Keiji
    Kouno, Hirotaka
    Kohno, Hiroshi
    Morio, Kei
    Moriya, Takashi
    Nonaka, Michihiro
    Aisaka, Yasuyuki
    Masaki, Keiichi
    Honda, Yohji
    Naeshiro, Noriaki
    Hiramatsu, Akira
    Aikata, Hiroshi
    Oka, Shiro
    ONCOLOGY, 2024, 102 (03) : 239 - 251
  • [27] BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
    Amadeo, E.
    Persano, M.
    Tada, T.
    Suda, G.
    Shimose, S.
    Kudo, M.
    Yoo, C.
    Rossari, F.
    Vitiello, F.
    Gardini, A. Casadei
    Rimini, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1539 - S1540
  • [28] Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma.
    Park, Young-Gyu
    Kim, Hyung-Don
    Kim, Sejin
    Kim, Kyu-Pyo
    Park, Sook Ryun
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Yoo, Changhoon
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 467 - 467
  • [29] Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series
    Ichimura, Takenori
    Ichikura, Daisuke
    Hinata, Miwa
    Hida, Noriko
    Baba, Toshiyuki
    SAGE OPEN MEDICAL CASE REPORTS, 2023, 11
  • [30] Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
    Yano, Shigeki
    Kawaoka, Tomokazu
    Yamasaki, Shintaro
    Johira, Yusuke
    Kosaka, Masanari
    Shirane, Yuki
    Miura, Ryoichi
    Amioka, Kei
    Naruto, Kensuke
    Yamaoka, Kenji
    Fujii, Yasutoshi
    Uchikawa, Shinsuke
    Fujino, Hatsue
    Ono, Atsushi
    Nakahara, Takashi
    Murakami, Eisuke
    Miki, Daiki
    Tsuge, Masataka
    Teraoka, Yuji
    Kouno, Hirotaka
    Takaki, Shintaro
    Mori, Nami
    Tsuji, Keiji
    Oka, Shiro
    CANCERS, 2023, 15 (22)
12345